CDK2 and colorectal cancer: Docking studies further reinforced the biological relevance of the Ru(III) complex, which showed favorable interactions with cyclin-dependent kinase 2 (CDK2), a key regulator of cell cycle progression often upregulated in colorectal cancers [112].